Wellfully Limited, together with its subsidiaries, develops dermaportation and enhanced transdermal polymer technologies for use in the pharmaceutical, cosmetic and skincare, and consumer healthcare sectors in Singapore and Europe.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.12|
|52 Week High||AU$0.047|
|52 Week Low||AU$0.19|
|1 Month Change||-32.35%|
|3 Month Change||57.53%|
|1 Year Change||-36.11%|
|3 Year Change||-69.74%|
|5 Year Change||-92.43%|
|Change since IPO||-99.86%|
Recent News & Updates
|WFL||AU Pharmaceuticals||AU Market|
Return vs Industry: WFL underperformed the Australian Pharmaceuticals industry which returned 6.7% over the past year.
Return vs Market: WFL underperformed the Australian Market which returned 21.1% over the past year.
Stable Share Price: WFL is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 22% a week.
Volatility Over Time: WFL's weekly volatility has increased from 14% to 22% over the past year.
About the Company
Wellfully Limited, together with its subsidiaries, develops dermaportation and enhanced transdermal polymer technologies for use in the pharmaceutical, cosmetic and skincare, and consumer healthcare sectors in Singapore and Europe. It operates in two segments, Dermaportation Drug Delivery Technology and Devices. It develops magnetic micro-array and powerless drug delivery technologies; and designs and develops drug patches, applicators, and brushes products.
Wellfully Fundamentals Summary
|WFL fundamental statistics|
Is WFL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|WFL income statement (TTM)|
|Cost of Revenue||AU$1.01m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.03|
|Net Profit Margin||-531.62%|
How did WFL perform over the long term?See historical performance and comparison
Is Wellfully undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate WFL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate WFL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: WFL is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.
PE vs Market: WFL is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate WFL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: WFL is overvalued based on its PB Ratio (10.5x) compared to the AU Pharmaceuticals industry average (3.5x).
How is Wellfully forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wellfully has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Wellfully performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: WFL is currently unprofitable.
Growing Profit Margin: WFL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: WFL is unprofitable, and losses have increased over the past 5 years at a rate of 12% per year.
Accelerating Growth: Unable to compare WFL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: WFL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).
Return on Equity
High ROE: WFL has a negative Return on Equity (-277.1%), as it is currently unprofitable.
How is Wellfully's financial position?
Financial Position Analysis
Short Term Liabilities: WFL's short term assets (A$3.0M) exceed its short term liabilities (A$1.0M).
Long Term Liabilities: WFL's short term assets (A$3.0M) exceed its long term liabilities (A$61.7K).
Debt to Equity History and Analysis
Debt Level: WFL's debt to equity ratio (6.7%) is considered satisfactory.
Reducing Debt: WFL's debt to equity ratio has increased from 2.9% to 6.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: WFL has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: WFL has less than a year of cash runway if free cash flow continues to reduce at historical rates of 12.1% each year
What is Wellfully current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate WFL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate WFL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if WFL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if WFL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of WFL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Paul Peros serves as Chief Executive Officer of Wellfully Limited (formerly known as OBJ Limited) since April 14, 2020. He was Chief Executive Officer of New Beauty Technology Division at Wellfully Lim...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD676.60K) is above average for companies of similar size in the Australian market ($USD303.55K).
Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.
Experienced Board: WFL's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 43.2%.
Wellfully Limited's employee growth, exchange listings and data sources
- Name: Wellfully Limited
- Ticker: WFL
- Exchange: ASX
- Founded: 1992
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$24.130m
- Shares outstanding: 209.82m
- Website: https://www.wellfully.net
- Wellfully Limited
- 284 Oxford Street
- Ground Floor
- Western Australia
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/21 18:05|
|End of Day Share Price||2021/10/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.